Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 274-303

  Schmitt, J ^a,b   Rosumeck, S ^c   Thomaschewski, G ^a   Sporbeck, B ^c   Haufe, E ^a   Nast, A ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTORS; CYCLOSPORINE; DERMATOLOGIC AGENTS; FUMARATES; HUMANS; METHOTREXATE; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOIDS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84890445111     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12663     Document Type: Review

References (68)

1. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
2. de Korte J, Sprangers MA, Mombers FM, Bos JD,. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9: 140-7.
3. Stern RS, Nijsten T, Feldman SR, et al,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-9.
4. Schmitt J, Ford DE,. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-10.
5. Schmitt J, Ford DE,. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis-a structural equations modeling approach. Gen Hosp Psychiatry 2007; 29: 134-40.
6. Nijsten T, Wakkee M,. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009; 129: 1601-3.
7. Samarasekera EJ, Neilson JM, Warren RB, et al,. Incidence of cardiovascular disease in people with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-6.
8. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
9. Chaudhari U, Romano P, Mulcahy LD, et al,. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
10. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
11. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
12. Ellis CN, Krueger GG,. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
13. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
14. Schmitt J, Zhang Z, Wozel G, et al,. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26.
15. Nast A, Boehncke WH, Mrowietz U, et al,. [S3-guidelines for the treatment of psoriasis vulgaris. Update 2011]. J Dtsch Dermatol Ges 2011; 9 (Suppl. 2): S1-104. (in German).
16. Higgins JP, Altman DG, Gøtzsche PC, et al,. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
17. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
18. Glenny AM, Altman DG, Song F, et al,. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1-134, iii-iv.
19. Ellis CN, Fradin MS, Messana JM, et al,. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-84.
20. Laburte C, Grossman R, Abi-Rached J, et al,. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366-75.
21. Mahrle G, Schulze HJ, Färber L, et al,. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88.
22. Gisondi P, Del Giglio M, Di Francesco V, et al,. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-7.
23. Flytström I, Stenberg B, Svensson A, Bergbrant IM,. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-21.
24. Yoon HS, Youn JI,. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat 2007; 18: 286-90.
25. Heydendael VM, Spuls PI, Opmeer BC, et al,. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65.
26. Thaçi D, Bräutigam M, Kaufmann R, et al,. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 2002; 205: 383-8.
27. Koo J,. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998; 139: 88-95.
28. -1) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 1997; 77: 137-41.
29. Altmeyer PJ, Matthes U, Pawlak F, et al,. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
30. Fallah Arani S, Neumann H, Hop WC, Thio HB,. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol 2011; 164: 855-61.
31. Ho SG, Yeung CK, Chan HH,. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life. Clin Exp Dermatol 2010; 35: 717-22.
32. Dogra S, Krishna V, Kanwar AJ,. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol 2012; 37: 729-34.
33. Caproni M, Antiga E, Melani L, et al,. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009; 29: 210-14.
34. Gisondi P, Del Giglio M, Cotena C, Girolomoni G,. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008; 158: 1345-9.
35. Revicki D, Willian MK, Saurat JH, et al,. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-57.
36. Asahina A, Nakagawa H, Etoh T, et al,. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
37. Gordon KB, Langley RG, Leonardi C, et al,. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
38. Krueger GG, Papp KA, Stough DB, et al,. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33.
39. Ortonne JP,. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17 (Suppl. 2): 12-16.
40. Bagel J, Lynde C, Tyring S, et al,. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012; 67: 86-92.
41. Gottlieb AB, Leonardi C, Kerdel F, et al,. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 652-60.
42. Strober BE, Crowley JJ, Yamauchi PS, et al,. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 661-8.
43. Sterry W, Ortonne JP, Kirkham B, et al,. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147.
44. Cassano N, Loconsole F, Miracapillo A, et al,. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group. Int J Immunopathol Pharmacol 2010; 23: 797-802.
45. van de Kerkhof PC, Segaert S, Lahfa M, et al,. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-85.
46. Moore A, Gordon KB, Kang S, et al,. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56: 598-603.
47. Tyring S, Gottlieb A, Papp K, et al,. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
48. Cassano N, Miracapillo A, Coviello C, et al,. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig 2006; 26: 227-33.
49. Papp KA, Tyring S, Lahfa M, et al,. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12.
50. Gottlieb AB, Matheson RT, Lowe N, et al,. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
51. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
52. Antoni CE, Kavanaugh A, Kirkham B, et al,. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-36.
53. Reich K, Nestle FO, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
54. Menter A, Feldman SR, Weinstein GD, et al,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-15.
55. Torii H, Nakagawa H,. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-9.
56. Yang HZ, Wang K, Jin HZ, et al,. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl) 2012; 125: 1845-51.
57. Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
58. Gottlieb A, Menter A, Mendelsohn A, et al,. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-40.
59. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
60. Griffiths CE,. Comparing biological therapies in psoriasis: implications for clinical practice. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 6): 10-14.
61. Tsai TF, Ho JC, Song M, et al,. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-63.
62. Igarashi A, Kato T, Kato M, et al,. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-52.
63. Nast A, Sporbeck B, Rosumeck S, et al,. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol 2013; 133: 1963-70.
64. Moher D, Liberati A, Tetzlaff J, et al,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-41.
65. Lucka TC, Pathirana D, Sammain A, et al,. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012; 26: 1331-44.
66. Spuls PI, Lecluse LL, Poulsen ML, et al,. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010; 130: 933-43.
67. Papoutsaki M, Talamonti M, Giunta A, et al,. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010; 221 (Suppl. 1): 43-7.
68. Mrowietz U, de Jong EM, Kragballe K, et al,. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2013; doi: 10.1111/jdv.12118. [Epub ahead of print].